Expression of integrin α‑6 is associated with multi drug resistance and prognosis in ovarian cancer

Wei,Luwei; Yin,Fuqiang; Chen,Changxian; Li,Li

doi:10.3892/ol.2019.10056

Expression of integrin α‑6 is associated with multi drug resistance and prognosis in ovarian cancer

Authors:
- Luwei Wei
- Fuqiang Yin
- Changxian Chen
- Li Li
View Affiliations

Affiliations: Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: February 20, 2019 https://doi.org/10.3892/ol.2019.10056
Pages: 3974-3980

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is a serious threat to women's health. Multidrug resistance is a major cause of post‑treatment relapse, metastasis, and even mortality. This characteristic severely restricts the survival of patients with ovarian cancer. Integrin α‑6 (ITGA6) is a member of the adhesion molecule family that conducts signals through interactions between the extracellular domain and the matrix, serving important roles in cell adhesion‑mediated drug resistance, which is considered to have a critical function in ovarian cancer drug resistance. The association between ITGA6 and ovarian cancer multidrug resistance has been investigated only rarely, to the best of our knowledge. Using RT‑qPCR and immunohistochemistry, it was identified that ITGA6 is a central drug resistance gene, and that its expression was upregulated in cisplatin‑resistant SKOV3 (SKOV3/DDP2), cisplatin‑resistant A2780 (A2780/DDP) cells, and in 54 cases of drug‑resistant tissues, as compared with in the controls. Furthermore, bioinformatics and text mining performed by Coremine Medical (http://www.coremine.com/medical/#search) confirmed that ITGA6 was significantly associated with ovarian cancer and drug resistance. Additionally, the high expression of ITGA6 is associated with a poor outcome. The present study provides the basis for further understanding the role of ITGA6 in the regulation of drug resistance in ovarian cancer, and demonstrates that it could be a potential marker for the prognosis of ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
3	Groeneweg JW, Foster R, Growdon WB, Verheijen RH and Rueda BR: Notch signaling in serous ovarian cancer. J Ovarian Res. 7:952014. View Article : Google Scholar : PubMed/NCBI
4	Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS: The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
5	Tuorkey MJ: Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci. 6:139–146. 2014.PubMed/NCBI
6	Han X, DU F, Jiang L, Zhu Y, Chen Z, Liu Y, Hong T, Wang T, Mao Y, Wu X, et al: A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties. Oncol Lett. 6:1295–1298. 2013. View Article : Google Scholar : PubMed/NCBI
7	Yan L, Wang C, Lin B, Liu J, Liu D, Hou R, Wang Y, Gao L, Zhang S and Iwamori M: Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression. Biochimie. 113:17–25. 2015. View Article : Google Scholar : PubMed/NCBI
8	De Marco R, Tolomelli A, Juaristi E and Gentilucci L: Integrin ligands with α/β-hybrid peptide structure: Design, bioactivity, and conformational aspects. Med Res Rev. 36:389–424. 2016. View Article : Google Scholar : PubMed/NCBI
9	Blandin AF, Renner G, Lehmann M, Lelong-Rebel I, Martin S and Dontenwill M: β1 Integrins as therapeutic targets to disrupt hallmarks of cancer. Front Pharmacol. 6:2792015. View Article : Google Scholar : PubMed/NCBI
10	Burkhalter RJ, Symowicz J, Hudson LG, Gottardi CJ and Stack MS: Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem. 286:23467–23475. 2011. View Article : Google Scholar : PubMed/NCBI
11	Elliott T and Sethi T: Integrins and extracellular matrix: A novel mechanism of multidrug resistance. Expert Rev Anticancer Ther. 2:449–459. 2002. View Article : Google Scholar : PubMed/NCBI
12	Yamakawa N, Kaneda K, Saito Y, Ichihara E and Morishita K: The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. PLoS One. 7:e307062012. View Article : Google Scholar : PubMed/NCBI
13	Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, Schörg A, Gotwald L, Fan M, Wenger RH and Seagroves TN: ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer. 15:262016. View Article : Google Scholar : PubMed/NCBI
14	Yin F, Liu L, Liu X, Li G, Zheng L, Li D, Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. Oncol Rep. 32:362–372. 2014. View Article : Google Scholar : PubMed/NCBI
15	Prat J: FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 104:177–178. 2009. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Luvero D, Milani A and Ledermann JA: Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
18	Jia Y, Zeng ZZ, Markwart SM, Rockwood KF, Ignatoski KM, Ethier SP and Livant DL: Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res. 64:8674–8681. 2004. View Article : Google Scholar : PubMed/NCBI
19	Dransfield I, Cabanas C, Barrett J and Hogg N: Interaction of leukocyte integrins with ligand is necessary but not sufficient for function. J Cell Biol. 116:1527–1535. 1992. View Article : Google Scholar : PubMed/NCBI
20	Janouskova H, Ray AM, Noulet F, Lelong-Rebel I, Choulier L, Schaffner F, Lehmann M, Martin S, Teisinger J and Dontenwill M: Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target alpha5 integrin in colon cancer cells. Cancer Lett. 336:307–318. 2013. View Article : Google Scholar : PubMed/NCBI
21	Toquet C, Colson A, Jarry A, Bezieau S, Volteau C, Boisseau P, Merlin D, Laboisse CL and Mosnier JF: ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int J Cancer. 130:278–287. 2012. View Article : Google Scholar : PubMed/NCBI
22	Maubant S, Cruet-Hennequart S, Poulain L, Carreiras F, Sichel F, Luis J, Staedel C and Gauduchon P: Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer. 97:186–194. 2002. View Article : Google Scholar : PubMed/NCBI
23	Kim HI, Huang H, Cheepala S, Huang S and Chung J: Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion. Cancer Prev Res (Phila). 1:385–391. 2008. View Article : Google Scholar : PubMed/NCBI
24	Linhares MM, Affonso RJ Jr, Viana Lde S, Silva SR, Denadai MV, de Toledo SR and Matos D: Genetic and immunohistochemical expression of integrins ITGAV, ITGA6, and ITGA3 As prognostic factor for colorectal cancer: Models for global and disease-free survival. PLoS One. 10:e01443332015. View Article : Google Scholar : PubMed/NCBI
25	Marthick JR and Dickinson JL: Emerging putative biomarkers: The role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. Prostate Cancer. 2012:2987322012. View Article : Google Scholar : PubMed/NCBI